Overview

Financials

News Ideas Discussions Technicals Forecast Seasonals Options

IMMX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪47.13 M‬USD

—

−0.79USD

2012

Ilya Rachman

immixbio.com

About

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Ownership

‪‪27.72 M‬‬

Free Float shares

‪‪16.51 M‬‬ (59.55%)

Closely held shares

‪‪11.21 M‬‬ (40.45%)

Free Float shares

‪‪16.51 M‬‬ (59.55%)

Closely held shares

‪‪11.21 M‬‬ (40.45%)

Capital structure

Market cap

‪‪47.13 M‬‬

Debt

‪‪1.07 M‬‬

Cash & equivalents

‪‪17.68 M‬‬

Enterprise value

‪‪30.52 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪47.13 M‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

—

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

—

Valuation ratios

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Growth and Profitability

Company’s recent performance and margins

Performance

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−8.00 M‬‬

‪‪−6.00 M‬‬

‪‪−4.00 M‬‬

‪‪−2.00 M‬‬

‪0.00‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−5.20 M‬‬

‪‪−3.90 M‬‬

‪‪−2.60 M‬‬

‪‪−1.30 M‬‬

‪0.00‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−5.20 M‬‬

‪‪−3.90 M‬‬

‪‪−2.60 M‬‬

‪‪−1.30 M‬‬

‪0.00‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪0.00‬

Estimate

Earnings

Next:May 28, 2025

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪−0.28‬

‪−0.21‬

‪−0.14‬

‪−0.07‬

‪0.00‬

Actual

Estimate

Dividends

Dividend yield, history and sustainability

IMMX does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−10.00 M‬‬

‪0.00‬

‪‪10.00 M‬‬

‪‪20.00 M‬‬

‪‪30.00 M‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪5.50 M‬‬

‪‪11.00 M‬‬

‪‪16.50 M‬‬

‪‪22.00 M‬‬

Assets

Liabilities